Radiopharmaceutical producer Nuclear Research and Consultancy Group (NRG) received approval from the Dutch government on January 20 to proceed with a new nuclear research reactor to replace an existing reactor in Petten.
The new Pallas reactor is scheduled to go online by 2022 and will produce the medical isotope molybdenum-99 (Mo-99), the precursor to technetium-99m, which is used for nuclear cardiology applications.
The Petten reactor supplies approximately one-third of the global demand for Mo-99 and approximately 60% of Europe's demand, according to NRG.
